Opus Genetics, Inc. (IRD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Opus Genetics reported revenue of $14.2M, up 29.1% from $11.0M the year before. Net income was -$49.6M (a -349.3% net margin), or -$0.80 per diluted share. Operating margin was -271.9%. Operating activities generated -$35.3M of cash. At fiscal year end, Opus Genetics held $50.2M in total assets against $34.9M in total liabilities, including $45.1M of cash and equivalents.
Open the full interactive Opus Genetics financials → Quarterly statements, key ratios, valuation history and price charts.
Opus Genetics Key Stats
| Share Price | $4.24 |
|---|---|
| Market Cap | $472.3M |
| Revenue YoY Growth | +29.1% |
| 52-Week Range | $1.74 – $6.07 |
| Shares Outstanding | 95.5 million (basic, 2026 Q2) |
Opus Genetics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $589,000 | $39.9M | $19.0M | $11.0M | $14.2M |
| Operating Income | -$20.0M | -$22.7M | $18.2M | -$10.6M | -$62.1M | -$38.6M |
| Pre-Tax Income | -$24.6M | -$56.7M | $18.2M | -$10.0M | -$57.5M | -$49.6M |
| Income Tax | $0 | $0 | $315,000 | $12,000 | $0 | $0 |
| Net Income | -$24.6M | -$56.7M | $17.9M | -$10.0M | -$57.5M | -$49.6M |
| Diluted EPS | -$5.28 | -$3.82 | $0.87 | -$0.46 | -$2.15 | -$0.80 |
Opus Genetics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.1M | $3.9M | $2.2M | $755,000 |
| Net Income | -$17.5M | -$16.5M | -$65.5M | -$8.1M |
| Diluted EPS | -$0.25 | -$0.27 | -$0.75 | -$0.14 |
Opus Genetics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $42.6M | $50.5M | $30.3M | $45.1M |
| Current Assets | $17.7M | $26.1M | $49.0M | $53.9M | $36.6M | $50.0M |
| Total Assets | $17.7M | $26.1M | $49.0M | $53.9M | $36.9M | $50.2M |
| Current Liabilities | $3.2M | $3.9M | $2.8M | $4.0M | $11.3M | $7.8M |
| Total Long-Term Debt | — | — | — | — | — | $1.1M |
| Total Liabilities | $31.1M | $3.9M | $2.8M | $4.0M | $11.3M | $34.9M |
| Shareholders' Equity | -$13.5M | $22.2M | $46.2M | $49.9M | $6.7M | $15.3M |
Opus Genetics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$6.8M | -$19.4M | $14.3M | -$1.1M | -$25.6M | -$35.3M |
| Cash From Investing | $539,000 | -$100,000 | $0 | $0 | $1.2M | $0 |
| Cash From Financing | $21.1M | $27.6M | $3.8M | $9.0M | $4.2M | $50.0M |
| Free Cash Flow | -$6.8M | — | — | — | — | — |
Figures from Opus Genetics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Opus Genetics financials page for every line item.
Opus Genetics Company Profile
| Ticker | IRD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Durham, North Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001228627 |
Frequently Asked Questions
What was Opus Genetics' revenue in fiscal 2025?
Opus Genetics (IRD) reported revenue of $14.2M for fiscal 2025.
What is Opus Genetics' annual revenue history?
Opus Genetics' annual revenue by fiscal year: 2020: $0; 2021: $589,000; 2022: $39.9M; 2023: $19.0M; 2024: $11.0M; 2025: $14.2M.
What was Opus Genetics' net income in fiscal 2025?
Opus Genetics reported net income of -$49.6M for fiscal 2025.
What was Opus Genetics' earnings per share (EPS) in fiscal 2025?
Opus Genetics' diluted EPS was -$0.80 for fiscal 2025 (adjusted for any later stock splits).
What was Opus Genetics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Opus Genetics reported revenue of $755,000.
How much debt does Opus Genetics have?
Opus Genetics reported $1.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Opus Genetics are outstanding?
Opus Genetics reported a weighted average of 95.5 million basic shares outstanding in 2026 Q2.
What is Opus Genetics' market cap?
Based on its latest closing price, Opus Genetics (IRD) has a market capitalization of about $472.3M.
When does Opus Genetics' fiscal year end?
Opus Genetics' fiscal year end, as registered with the SEC, is December 31.
Where is Opus Genetics headquartered?
Opus Genetics lists its business address in Durham, North Carolina in its SEC filings.